When targeting the blood-stage malaria antigen MSP1, high level antibody-mediated protection could be achieved in the P. yoelii mouse model of blood-stage malaria infection by using a priming immunization with a recombinant human adenovirus serotype 5 (AdHu5) vector followed by a booster immunization with the poxvirus vector modified vaccinia virus Ankara (MVA) [28]. Here, ATAD1 is linked to malaria.